Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO) announced its quarterly earnings data on Wednesday. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.01), FiscalAI reports.

Lexeo Therapeutics Trading Down 3.0%

LXEO traded down $0.15 during midday trading on Friday, hitting $4.81. 64,017 shares of the company traded hands, compared to its average volume of 950,816. The business has a 50 day simple moving average of $4.64 and a two-hundred day simple moving average of $5.63. Lexeo Therapeutics has a 52-week low of $3.99 and a 52-week high of $10.99. The company has a market capitalization of $377.84 million, a price-to-earnings ratio of -4.19 and a beta of 1.46.

Insider Transactions at Lexeo Therapeutics

In related news, insider Narinder Pal Bhalla sold 22,306 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the transaction, the insider owned 82,194 shares in the company, valued at $363,297.48. This represents a 21.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the transaction, the chief executive officer owned 377,817 shares in the company, valued at approximately $1,692,620.16. This trade represents a 6.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 62,204 shares of company stock valued at $280,089 in the last three months. Corporate insiders own 2.00% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. purchased a new stake in Lexeo Therapeutics in the fourth quarter valued at $4,598,000. Vestal Point Capital LP grew its holdings in shares of Lexeo Therapeutics by 37.7% during the 4th quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after purchasing an additional 1,225,000 shares during the period. Virtus Investment Advisers LLC acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth about $270,000. Wellington Management Group LLP acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth about $826,000. Finally, Susquehanna Portfolio Strategies LLC raised its holdings in Lexeo Therapeutics by 14.4% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 26,205 shares of the company’s stock valued at $260,000 after buying an additional 3,296 shares during the period. 60.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on LXEO. JPMorgan Chase & Co. decreased their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Weiss Ratings cut Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Lexeo Therapeutics presently has an average rating of “Buy” and a consensus price target of $18.75.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.